Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Why is a third COVID-19 vaccine dose important for people who are immunocompromised?

1 Sep, 2021 | 09:57h | UTC

Why is a third COVID-19 vaccine dose important for people who are immunocompromised? – The Conversation

Related:

FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

 

Study demonstrates a significantly higher humoral immunogenicity induced by the SARS-CoV-2 Moderna vaccine compared with the Pfizer- BioNTech vaccine.

31 Aug, 2021 | 09:04h | UTC

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 – JAMA

Related:

Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

 

New CDC Guidance says influenza and Covid vaccines can be given together – “COVID-19 vaccines and other vaccines may now be administered without regard to timing”

29 Aug, 2021 | 18:51h | UTC

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021–22 Influenza Season – Centers for Disease Control and Prevention

Related: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States – Centers for Disease Control and Prevention

Commentary: Flu shot and a COVID jab? New 2021-2022 flu vaccine guidance points to both – McKnight’s

 

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

27 Aug, 2021 | 10:11h | UTC

Press release: Is COVID vaccine protection fading? – ZOE Covid Study

Commentaries:

Covid infection protection waning in double jabbed – BBC

Expert reaction to press release from the ZOE app on vaccine effectiveness over time – Science Media Centre

 

[Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.

27 Aug, 2021 | 10:16h | UTC

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections – medRxiv

Commentary: Having SARS-CoV-2 once confers much greater immunity than a vaccine—but no infection parties, please – Science

 

Commentary on Twitter (thread – click for more)

https://twitter.com/andrew_croxford/status/1430799815693250562

 

Johnson & Johnson booster shot prompts large increase in immune response, company says.

26 Aug, 2021 | 09:14h | UTC

Johnson & Johnson booster shot prompts large increase in immune response, company says – CNN

News release: Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

 

Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.

26 Aug, 2021 | 08:32h | UTC

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery – International Journal of Gynecological Cancer

Editorial: Standardizing ovarian cancer surgery and peri-operative care: a European Society of Gynecological Oncology (ESGO) consensus statement

 

Covid-19 booster vaccines: What we know and who’s doing what.

24 Aug, 2021 | 10:04h | UTC

Covid-19 booster vaccines: What we know and who’s doing what – The BMJ

 

Opinion | The FDA really did have to take this long – “If vaccine approval feels maddeningly scrupulous, that’s because the alternative is worse”.

24 Aug, 2021 | 10:01h | UTC

The FDA Really Did Have to Take This Long – The Atlantic

 

COVID vaccines protect against Delta, but their effectiveness wanes.

24 Aug, 2021 | 09:57h | UTC

COVID vaccines protect against Delta, but their effectiveness wanes – Nature

Original study: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

 

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

22 Aug, 2021 | 23:51h | UTC

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Invited Commentary: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Related:

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

 

Commentary on Twitter

 

[Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

20 Aug, 2021 | 10:03h | UTC

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK – University of Oxford

Commentaries:

Vaccines Are Less Effective Against Delta—And Pfizer’s Protection Wanes Rapidly—But Are The Best Way To Protect Against Covid, Large Study Finds – Forbes

Expert reaction to preprint looking at the impact of the delta variant on vaccine effectiveness – Science Media Centre

Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard

 

Commentary on Twitter

 

Studies: COVID vaccine protection waning against infection but not hospitalization.

19 Aug, 2021 | 09:05h | UTC

Studies: COVID vaccine protection waning against infection but not hospitalization – CIDRAP

Study 1: Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 – CDC Morbidity and Mortality Weekly Report

Study 2: Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021 – CDC Morbidity and Mortality Weekly Report

Study 3: New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021 – CDC Morbidity and Mortality Weekly Report

 

Commentary on Twitter (thread – click for more)

 

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

19 Aug, 2021 | 09:06h | UTC

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms – NIH News Releases

Original study: Early Convalescent Plasma for High-Risk Outpatients with Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

18 Aug, 2021 | 09:04h | UTC

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination – The Lancet

Related:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

 

Commentary on Twitter (thread – click for more)

 

FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.

16 Aug, 2021 | 01:22h | UTC

Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals – U.S. Food & Drug Administration

Commentaries:

Statement on FDA Authorization of Supplemental Vaccine Dose for Immunocompromised Patients – Infectious Diseases Society of America

CDC, FDA recommend COVID booster for immune-compromised – CIDRAP

FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised – STAT

The fine print: Understanding the new policy authorizing extra Covid vaccine doses for the immunocompromised – STAT

Covid booster: US approves third jab for the immunocompromised – BBC

CDC Committee Approves Third Covid-19 Shot For Immunocompromised People—Here’s Who Should Get One – Forbes

CDC Panel Recommends 3rd Vaccine Dose For Immunocompromised People – NPR

6 Things To Know If You’re Immunocompromised And Considering A 3rd Shot – NPR

CDC recommends third Covid-19 vaccine dose for certain immunocompromised people – CNN

 

Commentary on Twitter

 

Study suggests a potential protective benefit from MMR and TDP vaccines in reducing the risk of severe Covid-19 infections.

16 Aug, 2021 | 01:04h | UTC

Protective heterologous T cell immunity in COVID-19 induced by the trivalent Measles-Mumps-Rubella and Tetanus-Diptheria-Pertussis vaccine antigens – Med

 

Commentary on Twitter

 

Opinion: Time for a smart approach to boosters.

13 Aug, 2021 | 09:51h | UTC

Time for a Smart Approach to Boosters – Think Global Health

 

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

12 Aug, 2021 | 09:56h | UTC

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients – New England Journal of Medicine

Editorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients

Related:

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

 

Commentaries on Twitter

https://twitter.com/hildabast/status/1425576801850433537

 

RCT: Evaluation of Moderna mRNA vaccine in adolescents.

12 Aug, 2021 | 09:58h | UTC

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Related:

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

 

Commentaries on Twitter

 

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

12 Aug, 2021 | 09:05h | UTC

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Commentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Related:

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

 

Commentary on Twitter

 

Guideline: Diagnosis and management of cutaneous lupus erythematosus – Therapy, risk factors and other special topics.

12 Aug, 2021 | 08:55h | UTC

S2k guideline: Diagnosis and management of cutaneous lupus erythematosus – Part 2: Therapy, risk factors and other special topics – Journal of German Society of Dermatology

 

Brief review: Immunobullous disease.

12 Aug, 2021 | 08:37h | UTC

Immunobullous disease – Clinical Medicine Journal

 

Brief review: Advances in atopic dermatitis.

12 Aug, 2021 | 08:32h | UTC

Advances in atopic dermatitis – Clinical Medicine Journal

 

PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.

11 Aug, 2021 | 08:52h | UTC

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Invited Commentary: The use of inhaled corticosteroids in early-stage COVID-19

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.